Education
About Us
Working with TipRanks
Follow Us
IceCure Medical (ICCM)
NASDAQ:ICCM
ICCM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.48 - $1.66
Previous CloseN/A
Volume318.06K
Average Volume (3M)421.02K
Market Cap
$62.51M
Enterprise Value$54.00M
Total Cash (Recent Filing)$5.59M
Total Debt (Recent Filing)$540.00K
Price to Earnings (P/E)―
Beta0.07
Next Earnings
May 14, 2025EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding56,569,000
10 Day Avg. Volume497,146
30 Day Avg. Volume421,022
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)19.17
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit41.54
Enterprise Value/Ebitda-3.79
Forecast
1Y Price Target
$2.75Price Target Upside147.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Icecure Medical News
PremiumCompany Announcements
IceCure Medical Reports Growth and Awaits FDA Decision
PremiumCompany Announcements
IceCure Medical Ltd’s Earnings Call: Growth Amidst Challenges
PremiumCompany Announcements
IceCure Medical Sees 42% Growth in ProSense® Sales Amid Awaited FDA Decision---
Bulls Say, Bears Say
Bulls Say
Clinical SuccessThe vast body of data available on ProSense as a treatment for early-stage low-risk breast cancer was reviewed, supporting the potential for its cryoablation treatment in the US market.
Market OpportunityProSense cryoablation offers a minimally invasive alternative to lumpectomy for roughly 70,000 women diagnosed in the U.S. annually with early-stage low risk breast cancer.
Regulatory ApprovalThe FDA advisory panel supports the use of ProSense cryoablation, indicating a favorable outcome for potential FDA clearance.
Bears Say
Capital RequirementsThe company may need to raise additional capital, highlighting potential financial strain.
Financial PerformanceThe company's revenue for 4Q24 declined by 30% YoY, missing the projection of $1.2M.
Regulatory RisksRisks include failure of cryoablation systems in clinical trials, failure to secure regulatory approval, failure to achieve commercial success, and dilution risk.
---
Ownership Overview
―
Insiders
0.05% Mutual Funds
0.02% Other Institutional Investors
99.93% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ICCM FAQ
What was IceCure Medical’s price range in the past 12 months?
IceCure Medical lowest stock price was $0.48 and its highest was $1.66 in the past 12 months.
What is IceCure Medical’s market cap?
IceCure Medical’s market cap is $62.51M.
When is IceCure Medical’s upcoming earnings report date?
IceCure Medical’s upcoming earnings report date is May 14, 2025 which is in 45 days.
How were IceCure Medical’s earnings last quarter?
IceCure Medical released its earnings results on Mar 27, 2025. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of -$0.075 by -$0.005.
Is IceCure Medical overvalued?
According to Wall Street analysts IceCure Medical’s price is currently Undervalued.
Does IceCure Medical pay dividends?
IceCure Medical does not currently pay dividends.
What is IceCure Medical’s EPS estimate?
IceCure Medical’s EPS estimate is -0.08.
How many shares outstanding does IceCure Medical have?
IceCure Medical has 56,569,000 shares outstanding.
What happened to IceCure Medical’s price movement after its last earnings report?
IceCure Medical reported an EPS of -$0.08 in its last earnings report, missing expectations of -$0.075. Following the earnings report the stock price went down -3.509%.
Which hedge fund is a major shareholder of IceCure Medical?
Currently, no hedge funds are holding shares in ICCM
---
Icecure Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.75 (147.75% Upside)
$2.75 (147.75% Upside)
Blogger Sentiment
Bullish
ICCM Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.50%
12-Months-Change
Fundamentals
Return on Equity
-160.70%
Trailing 12-Months
Asset Growth
-23.36%
Trailing 12-Months
Company Description
IceCure Medical
IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
---
ICCM Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
IceCure Medical Ltd demonstrated strong sales growth and positive developments in product adoption and support from the FDA advisory panel, while facing challenges with a delayed FDA decision and increased net losses. The financial improvements in gross profit and margin were positive indicators, yet the increase in operating expenses and net loss were areas of concern.Read More>---
ICCM Stock 12 Month Forecast
Average Price Target
$2.75
▲(147.75% Upside)
Technical Analysis
Best Analysts Covering ICCM
1 Year
1 Year Success Rate
7/16 ratings generated profit
1 Year Average Return
+6.24%
reiterated a buy rating 2 days ago
Copying Anthony Vendetti's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of +6.24% per trade.
---